Literature DB >> 3782265

Leukocyte adherence inhibition in patients with nonmalignant disorders of the colon and colorectal cancer.

B Tank, R L Marquet, E Vennemans, D L Westbroek.   

Abstract

The tube leukocyte adherence inhibition (LAI) technique was used to investigate the antitumor immunity in two groups of patients generally considered to be at "high risk" of developing colorectal cancer. The first group comprised 21 patients with colorectal polyps and the second 12 patients with various forms of colitis. Also 29 patients with histologically confirmed colorectal cancer were tested. The tube LAI assay was performed using peripheral blood leukocytes from individual patients and crude extracts of colorectal and breast cancers. Positive LAI reactions were observed in 18 out of 29 (62%) patients with colorectal cancer, in 1 out of 21 (5%) patients with colorectal polyps and in 1 out of 12 (8%) patients with colitis. The results indicate that in confirmed cases of malignancies, sensitization to colon tumor-associated antigens could be detected in the tube LAI test, whereas, premalignant sensitization to these antigens in "high risk" groups of patients could not be demonstrated.

Entities:  

Mesh:

Year:  1986        PMID: 3782265     DOI: 10.1007/bf00395923

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND.

Authors:  A B Gutman; E B Gutman
Journal:  J Clin Invest       Date:  1938-07       Impact factor: 14.808

2.  Separation of blood leucocytes, granulocytes and lymphocytes.

Authors:  A Boyum
Journal:  Tissue Antigens       Date:  1974

3.  Alpha-fetoprotein as a marker of embryo-specific differentiations in normal and tumor tissues.

Authors:  G I Abelev
Journal:  Transplant Rev       Date:  1974

4.  Prospective evaluation of the leukocyte adherence inhibition (LAI) test in breast cancer using a panel of extracts from known and unknown primary tumors.

Authors:  D Fritze; G Fedra; M Kaufmann
Journal:  Int J Cancer       Date:  1982-03-15       Impact factor: 7.396

5.  Leukocyte adherence inhibition (LAI) tests in patients clinically suspected of having breast cancer using a panel of breast carcinoma extracts.

Authors:  D Fritze; C Schulte-Uentrop; M Kaufmann
Journal:  Eur J Cancer       Date:  1979-12       Impact factor: 9.162

6.  Leukocyte adherence inhibition: tumor specificity of cellular and serum-blocking reactions in human melanoma, breast cancer, and colorectal cancer.

Authors:  W J Halliday; T A Koppi; J M Khan; N C Davis
Journal:  J Natl Cancer Inst       Date:  1980-08       Impact factor: 13.506

7.  Evidence for the expression of human tumor-specific antigens associated with beta2-microglobulin in human cancer and in some colon adenomas and benign breast lesions.

Authors:  D M Thomson; D N Tataryn; R O'Connor; J Rauch; P Friedlander; P Gold; J Shuster
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

8.  A comparison of tube leukocyte adherence inhibition assay and standard physical methods for diagnosing colorectal cancer.

Authors:  A O Ayeni; D M Thomson; J K MacFarlane; D Daly
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

9.  Failure of leucocyte-adherence-inhibition assays to discriminate between benign and malignant breast diseases.

Authors:  B M Vose; R Hughes; G W Bazill
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640

10.  Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition.

Authors:  J H Marti; D M Thomson
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.